Loading…

Treatment outcome of superficial leiomyosarcoma

Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2021-01, Vol.123 (1), p.127-132
Main Authors: Wellings, Elizabeth P., Tibbo, Meagan E., Rose, Peter S., Folpe, Andrew L., Houdek, Matthew T.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3
cites cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3
container_end_page 132
container_issue 1
container_start_page 127
container_title Journal of surgical oncology
container_volume 123
creator Wellings, Elizabeth P.
Tibbo, Meagan E.
Rose, Peter S.
Folpe, Andrew L.
Houdek, Matthew T.
description Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy. Results The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03). Conclusions The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.
doi_str_mv 10.1002/jso.26262
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2451848721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2472771629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</originalsourceid><addsrcrecordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdvJ526OUvyk0IP1HNJsAlt2m5rsIv33Rrd6EGQOc5iHl-FF6BLDFAOQ2Sb6KRFpjtAYgxS5BFkeo3G6kZwVEkboLMYNAEgp2CkaUQqCUirGaLYKVnet3XaZ7zvjW5t5l8V-Z4OrTa2brLG1b_c-6pCu-hydON1Ee3HYE_T2cL-aP-WL5ePz_G6RG8opySnlBa4YoUQaYzCrtMGlBqoNdwwqDsLZZNalJBo7YgnTHBdUANegJVnTCboZcnfBv_c2dqqto7FNo7fW91ERxnHJyoLgRK__0I3vwzZ9l1RBigILIpO6HZQJPsZgndqFutVhrzCorxZValF9t5js1SGxX7e2-pU_tSUwG8BH3dj9_0nq5XU5RH4CSMV5lw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472771629</pqid></control><display><type>article</type><title>Treatment outcome of superficial leiomyosarcoma</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</creator><creatorcontrib>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</creatorcontrib><description>Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy. Results The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03). Conclusions The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.26262</identifier><identifier>PMID: 33063336</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>dermal ; Female ; Follow-Up Studies ; Humans ; Incidence ; leiomyosarcoma ; Leiomyosarcoma - pathology ; Leiomyosarcoma - surgery ; Male ; Margins of Excision ; Medical prognosis ; Middle Aged ; Minnesota - epidemiology ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; outcome ; Postoperative Complications - epidemiology ; Postoperative Complications - mortality ; Postoperative Complications - pathology ; Prognosis ; Retrospective Studies ; subcutaneous ; superficial ; Survival Rate</subject><ispartof>Journal of surgical oncology, 2021-01, Vol.123 (1), p.127-132</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</citedby><cites>FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</cites><orcidid>0000-0003-0390-1018</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33063336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wellings, Elizabeth P.</creatorcontrib><creatorcontrib>Tibbo, Meagan E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><creatorcontrib>Houdek, Matthew T.</creatorcontrib><title>Treatment outcome of superficial leiomyosarcoma</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy. Results The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03). Conclusions The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</description><subject>dermal</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Incidence</subject><subject>leiomyosarcoma</subject><subject>Leiomyosarcoma - pathology</subject><subject>Leiomyosarcoma - surgery</subject><subject>Male</subject><subject>Margins of Excision</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Minnesota - epidemiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>outcome</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Complications - mortality</subject><subject>Postoperative Complications - pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>subcutaneous</subject><subject>superficial</subject><subject>Survival Rate</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdvJ526OUvyk0IP1HNJsAlt2m5rsIv33Rrd6EGQOc5iHl-FF6BLDFAOQ2Sb6KRFpjtAYgxS5BFkeo3G6kZwVEkboLMYNAEgp2CkaUQqCUirGaLYKVnet3XaZ7zvjW5t5l8V-Z4OrTa2brLG1b_c-6pCu-hydON1Ee3HYE_T2cL-aP-WL5ePz_G6RG8opySnlBa4YoUQaYzCrtMGlBqoNdwwqDsLZZNalJBo7YgnTHBdUANegJVnTCboZcnfBv_c2dqqto7FNo7fW91ERxnHJyoLgRK__0I3vwzZ9l1RBigILIpO6HZQJPsZgndqFutVhrzCorxZValF9t5js1SGxX7e2-pU_tSUwG8BH3dj9_0nq5XU5RH4CSMV5lw</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Wellings, Elizabeth P.</creator><creator>Tibbo, Meagan E.</creator><creator>Rose, Peter S.</creator><creator>Folpe, Andrew L.</creator><creator>Houdek, Matthew T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0390-1018</orcidid></search><sort><creationdate>202101</creationdate><title>Treatment outcome of superficial leiomyosarcoma</title><author>Wellings, Elizabeth P. ; Tibbo, Meagan E. ; Rose, Peter S. ; Folpe, Andrew L. ; Houdek, Matthew T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>dermal</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Incidence</topic><topic>leiomyosarcoma</topic><topic>Leiomyosarcoma - pathology</topic><topic>Leiomyosarcoma - surgery</topic><topic>Male</topic><topic>Margins of Excision</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Minnesota - epidemiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>outcome</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Complications - mortality</topic><topic>Postoperative Complications - pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>subcutaneous</topic><topic>superficial</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wellings, Elizabeth P.</creatorcontrib><creatorcontrib>Tibbo, Meagan E.</creatorcontrib><creatorcontrib>Rose, Peter S.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><creatorcontrib>Houdek, Matthew T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wellings, Elizabeth P.</au><au>Tibbo, Meagan E.</au><au>Rose, Peter S.</au><au>Folpe, Andrew L.</au><au>Houdek, Matthew T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment outcome of superficial leiomyosarcoma</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>123</volume><issue>1</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background Nonuterine leiomyosarcomas (LMS) are common extremity soft‐tissue sarcomas. Deep LMS are at an increased risk for recurrence; however, few studies have focused on superficial LMS. Methods We reviewed the clinicopathological features of 82 patients with a primary superficial LMS. The mean age and follow‐up were 57 ± 15 and 7 ± 5 years. Depth was classified as dermal (based in the skin; n = 35, 43%) and subcutaneous (based below the dermis, above the fascia; n = 47, 57%) on the final resection specimen. Dermal cases were treated with negative margin resection, while subcutaneous tumors were evaluated by a multidisciplinary team for consideration of possible adjuvant therapy. Results The 10‐year disease‐specific survival (DSS) for superficial LMS was 90% with no difference (p = .18) in the 10‐year DSS between patients with dermal (100%) and subcutaneous (86%) LMS. All disease recurrences occurred in subcutaneous LMS (17% vs. 0%, p = .02) and subcutaneous tumors had a worse10‐year metastatic free survival (81% vs. 100%, p = .03). Conclusions The results of this study suggest that dermal LMS can be managed with a negative margin resection alone. Although the prognosis for patients with subcutaneous LMS is quite favorable, there is some risk for local and distant recurrence, and such patients will benefit from multidisciplinary care.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33063336</pmid><doi>10.1002/jso.26262</doi><tpages>0</tpages><orcidid>https://orcid.org/0000-0003-0390-1018</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-4790
ispartof Journal of surgical oncology, 2021-01, Vol.123 (1), p.127-132
issn 0022-4790
1096-9098
language eng
recordid cdi_proquest_miscellaneous_2451848721
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects dermal
Female
Follow-Up Studies
Humans
Incidence
leiomyosarcoma
Leiomyosarcoma - pathology
Leiomyosarcoma - surgery
Male
Margins of Excision
Medical prognosis
Middle Aged
Minnesota - epidemiology
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - surgery
outcome
Postoperative Complications - epidemiology
Postoperative Complications - mortality
Postoperative Complications - pathology
Prognosis
Retrospective Studies
subcutaneous
superficial
Survival Rate
title Treatment outcome of superficial leiomyosarcoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20outcome%20of%20superficial%20leiomyosarcoma&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Wellings,%20Elizabeth%20P.&rft.date=2021-01&rft.volume=123&rft.issue=1&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.26262&rft_dat=%3Cproquest_cross%3E2472771629%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-33571d42329ccc14dac18a03ac5f40d506fe335b892a1f2e24a5173605a0a92b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2472771629&rft_id=info:pmid/33063336&rfr_iscdi=true